[Radioimmunoimaging of bladder tumor with the intravesical administration of technetium -99m labelled monoclonal antibody].
OBJECTIVE
To make radioimmunoimaging of bladder tumor simple, safe and reliable.


METHODS
Anti-human bladder carcinoma cell line BIU-87 monoclonal antibody-BDI-1 was labelled with technetium -99m by direct mercaptoethanol reducing method.


RESULTS
The labelling rate was 69.6% and the radiochemistry pruity was higher than 95%. 33 patients received radioimmunoimaging of bladder tumor with the intravesical administration of technetium -99m labelled monoclonal antibody. The false positive rate was zero. 88.5% of all 29 bladder cancer patients had got positive immunoscintigraphy results, and 65.2% of them were confirmed by cystoscopic results. Both primary and recurrent tumor could be detected clearly and the smallest tumor detected was 0.5 cm in diameter. There were some differences between the radioimmunoimaging and cystoscopic results in 7 of 11 multitumor cases, which included tumor size, number and location.


CONCLUSIONS
It is required to use more suitable isotopes and/or monoclonal antibodies to increase its sensitivity.
Li
N
N
Institute of Urology, Department of Urology, First Hospital of Beijing Medical University, Beijing 100034.
Yu
L
L
Zhang
C
C
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016719:Radioimmunodetection; D013667:Technetium; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging*
D000911:Antibodies, Monoclonal; D013667:Technetium